Fleischmann R, et al. A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib to Placebo and to Adalimumab, in Patients with Active Rheumatoid Arthritis with Inadequate Response to Methotrexate. ACR 2018, abstract 890.
Anti-C5a-antilichaam vilobelimab veilig bij ernstige COVID-19
feb 2021 | Pneumonie, Virale infecties